These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8611376)

  • 1. Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer.
    Gazet JC; Coombes RC; Ford HT; Griffin M; Corbishley C; Makinde V; Lowndes S; Quilliam J; Sutcliffe R
    Br J Cancer; 1996 Mar; 73(6):758-62. PubMed ID: 8611376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
    Gazet JC; Ford HT; Gray R; McConkey C; Sutcliffe R; Quilliam J; Makinde V; Lowndes S; Coombes RC
    Ann Oncol; 2001 May; 12(5):685-91. PubMed ID: 11432629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
    Makris A; Powles TJ; Dowsett M; Osborne CK; Trott PA; Fernando IN; Ashley SE; Ormerod MG; Titley JC; Gregory RK; Allred DC
    Clin Cancer Res; 1997 Apr; 3(4):593-600. PubMed ID: 9815725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
    Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
    Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone, mitomycin-C, methotrexate combination chemotherapy with radiotherapy and/or surgery in stage III (T4B, NO-2, M0) breast cancer.
    Raina V; Sharma A; Deo SV; Shukla NK; Mohanty BK; Goel A; Rath GK
    J Assoc Physicians India; 1998 Nov; 46(11):926-9. PubMed ID: 11229215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.
    Cameron DA; Anderson ED; Levack P; Hawkins RA; Anderson TJ; Leonard RC; Forrest AP; Chetty U
    Br J Cancer; 1997; 76(8):1099-105. PubMed ID: 9376273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
    Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
    Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
    Pritchard KI
    Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.
    Taylor CW; Green S; Dalton WS; Martino S; Rector D; Ingle JN; Robert NJ; Budd GT; Paradelo JC; Natale RB; Bearden JD; Mailliard JA; Osborne CK
    J Clin Oncol; 1998 Mar; 16(3):994-9. PubMed ID: 9508182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
    ; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
    Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer.
    Fallowfield L; McGurk R; Dixon M
    Eur J Cancer; 2004 Nov; 40(16):2403-10. PubMed ID: 15519512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
    Jonat W
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The place of chemotherapy in the treatment of early breast cancer.
    Buzdar A
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):16-20. PubMed ID: 9741784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.
    Masuda N; Iwata H; Rai Y; Anan K; Takeuchi T; Kohno N; Takei H; Yanagita Y; Noguchi S
    Breast Cancer Res Treat; 2011 Apr; 126(2):443-51. PubMed ID: 21221770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of LHRH agonists in premenopausal women with oestrogen receptor-positive breast cancer: the ZEBRA experience.
    Jonat W
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S39-40. PubMed ID: 12409069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.